LoadingLoadingLoadingNet selling: insiders sold $59.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Sells/Trims (3)
Citadel
$446.8M
trimmed
Qube Research
$188.1M
trimmed
Two Sigma
$92.6M
trimmed
Buys (1)
No tracked top-trader positions in CAH as of Oct 24, 04:45 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 11, 2026
Financial period
Q4 FY2026
Earnings per share
$2.42 expected
Revenue
$65.11B expected
Estimates as of Oct 24, 2026
EPS expected
$2.88 to $3.06
Revenue expected
11 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 11, 2026 | $2.91 / $2.42Alpha Vantage | +20.25% beat | $63.67B $65.11B expected | -2.20% miss |
| Mar 31, 2026 | Apr 30, 2026 | $3.17 / $2.79Yahoo Finance | +13.70% beat | $60.94B No estimate | Unavailable |
| Dec 31, 2025 | Feb 5, 2026 | $2.63 / $2.37Yahoo Finance | +11.17% beat | $65.44B No estimate | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $2.55 / $2.17Yahoo Finance | +17.60% beat | $64.01B No estimate | Unavailable |
| Jun 30, 2025 | Aug 12, 2025 | $2.08 / $2.03Alpha Vantage | +2.46% beat | $60.16B No estimate | Unavailable |
| Mar 31, 2025 | May 1, 2025 | $2.35 / $2.15Alpha Vantage | +9.30% beat | $54.88B No estimate | Unavailable |
| Dec 31, 2024 | Jan 30, 2025 | $1.93 / $1.76Alpha Vantage | +9.66% beat | $55.26B No estimate | Unavailable |
| Sep 30, 2024 | Nov 1, 2024 | $1.88 / $1.62Alpha Vantage | +16.05% beat | $52.28B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $64.01B | $65.44B | $60.94B | $63.86B |
| Cost of what it sold | $61.69B | $63.23B | $58.44B | $61.11B |
| Gross profit | $2.32B | $2.21B | $2.50B | $2.75B |
| What it spent | ||||
| Sales and admin | $1.46B | $1.50B | $1.54B | $1.63B |
| Other operating costs | $190.0M | — | $447.0M | $392.0M |
| Total operating expenses | $1.65B | $1.50B | $1.99B | $2.02B |
| What was left | ||||
| Operating profit | $668.0M | $707.0M | $509.0M | $729.0M |
| Interest on debt | $80.0M | $88.0M | $101.0M | $79.0M |
| Profit before tax | $598.0M | $630.0M | $392.0M | $554.0M |
| Tax | $144.0M | $159.0M | $12.0M | $154.0M |
| Net profit | $450.0M | $471.0M | $399.0M | $394.0M |
| EBITDA | $911.0M | $776.0M | $741.0M | $1.05B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
90% of healthcare organizations don't fully know whether payment takebacks could have been prevented.
Leans bullishOct 22Gilead Sciences, Inc. (GILD) stock price, news, quote and history - Yahoo Finance
Leans bullishOct 22Cardinal Health (CAH) Stock Looks Pricey On Its 7x Five Year Run
Leans bearishOct 22Mizuho raises target for Cardinal Health stock to USD 280
BullishOct 22Cardinal Health stock: Mizuho lifts target to USD 280 pre-market
BullishOct 22Cardinal Health, Inc. (CAH.BA) Stock Price, News, Quote & History
NeutralOct 22Cardinal Health Procedure Kits May Contain Recalled BD Alaris Infusion Sets Linked to Over- and Under-Infusion Risks
BearishOct 21IBD Stock Of The Day Tests New Buy Point As Indicators Suggest More Upside
BullishOct 21
